Arvinas CEO Randy Teel discussed what the company views as a major milestone for PROTACs and what comes next for the broader protein-degradation field. In an interview, Teel framed the modality’s evolution as moving from early proof toward more systematic programming of degradation biology. The coverage places PROTAC progress in context of clinical-stage development and the engineering challenges that accompany selecting suitable targetable proteins, ligands, and linker architectures. Teel’s comments emphasize how future differentiation may depend on improving degradation selectivity and tunability rather than only adding new targets. The exchange also signals investor and developer attention shifting toward the practical roadmap after the first generation of PROTACs—how more teams translate early successes into robust clinical assets.